Immunoglobulin Fc Fragments
"Immunoglobulin Fc Fragments" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
| Descriptor ID |
D007141
|
| MeSH Number(s) |
D12.644.541.500.697 D12.776.124.486.485.538.500 D12.776.124.486.485.680.697 D12.776.124.790.651.538.500 D12.776.124.790.651.680.660 D12.776.377.715.548.538.500 D12.776.377.715.548.680.660
|
| Concept/Terms |
Immunoglobulin Fc Fragments- Immunoglobulin Fc Fragments
- Fc Fragments, Immunoglobulin
- Immunoglobulins, Fc Fragment
- Fc Fragment Immunoglobulins
- Fragment Immunoglobulins, Fc
- Immunoglobulin Fc Fragment
- Fc Fragment, Immunoglobulin
- Immunoglobulins, Fc
- Fc Fragments
- Fc Immunoglobulins
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Fc Fragments".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Fc Fragments".
This graph shows the total number of publications written about "Immunoglobulin Fc Fragments" by people in this website by year, and whether "Immunoglobulin Fc Fragments" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 3 | 1 | 4 |
| 2016 | 0 | 1 | 1 |
| 2018 | 2 | 3 | 5 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoglobulin Fc Fragments" by people in Profiles.
-
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol. 2024 Nov 04; 26(11):2044-2060.
-
Is luspatercept the new standard of care in transfusion-dependent low-risk myelodysplastic syndromes? Clin Adv Hematol Oncol. 2024 Oct; 22(8):367-369.
-
Safety and efficacy of luspatercept for the treatment of anemia in?patients with myelofibrosis. Blood Adv. 2024 09 10; 8(17):4511-4522.
-
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Sep; 11(9):e646-e658.
-
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study. Ann Hematol. 2023 Feb; 102(2):311-321.
-
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with?ring sideroblasts. Blood. 2022 11 17; 140(20):2170-2174.
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 05; 36(5):1432-1435.
-
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. 2022 01 27; 139(4):624-629.
-
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
-
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021 04 01; 184(7):1804-1820.e16.